Compare VIVS & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIVS | FLGC |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.6M |
| IPO Year | N/A | 2021 |
| Metric | VIVS | FLGC |
|---|---|---|
| Price | $2.40 | $10.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.0K | 15.8K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $140,000.00 | ★ $57,609,000.00 |
| Revenue This Year | $42.38 | N/A |
| Revenue Next Year | $15.42 | $0.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 35.92 | 24.71 |
| 52 Week Low | $1.41 | $6.80 |
| 52 Week High | $21.96 | $81.90 |
| Indicator | VIVS | FLGC |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 47.58 |
| Support Level | $2.11 | $8.09 |
| Resistance Level | $2.40 | $13.70 |
| Average True Range (ATR) | 0.13 | 1.11 |
| MACD | 0.03 | 0.61 |
| Stochastic Oscillator | 54.92 | 37.63 |
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.